Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $909000.0.

  • Sangamo Therapeutics' Amortizatization of Intangibles changed 0.0% to $909000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 2049.76%. This contributed to the annual value of $4.3 million for FY2024, which is 4031.15% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Amortizatization of Intangibles of $909000.0 as of Q3 2025, which was down 0.0% from $904000.0 recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Amortizatization of Intangibles high stood at $10.6 million for Q4 2021, and its period low was -$909000.0 during Q2 2021.
  • For the 5-year period, Sangamo Therapeutics' Amortizatization of Intangibles averaged around $1.6 million, with its median value being $909000.0 (2024).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 43383.84% in 2021, then skyrocketed by 457906.98% in 2023.
  • Sangamo Therapeutics' Amortizatization of Intangibles (Quarter) stood at $10.6 million in 2021, then tumbled by 80.2% to $2.1 million in 2022, then plummeted by 43.63% to $1.2 million in 2023, then decreased by 24.37% to $894000.0 in 2024, then rose by 1.68% to $909000.0 in 2025.
  • Its last three reported values are $909000.0 in Q3 2025, $904000.0 for Q2 2025, and $904000.0 during Q1 2025.